[ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting
NQ Score
45/100
N1 Content Completeness
10
Key facts
- [ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting
- ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
- Source: TWSE
- Date: Wed May 27 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
- Citation
- [ScinoPharm] Announcement regarding the approval of the removal of non-compete restrictions for directors (including independent directors) and their representatives at the 116th Annual General Meeting (Wed May 27 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Wed May 27 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
AI Analysis
Frequently Asked Questions
- Q: What is a non-compete clause for directors?
- A: It is a legal restriction preventing directors from engaging in businesses that compete with the company they serve.
- Q: What are the key facts in this article?
- A: ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.
- Q: What is the direct answer?
- A: ScinoPharm announced that the 116th AGM approved the removal of non-compete restrictions for its directors, including Chairman Luo Chih-hsien, allowing them to hold concurrent positions in mainland China-based businesses.